Abstract GS03-12: Phase III study of adjuvant ado-trastuzumab emtansine vs. trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. San Antonio Breast Cancer Symposium 2023 - Loibl, S; Mano, M; Untch, M